By Chris Wack
Emergent BioSolutions said it agreed to pay $40 million to settle previously disclosed securities class-action litigation pending in the U.S. District Court for the District of Maryland.
Under the terms of the proposed settlement, the Gaithersburg, Md., biopharmaceutical company Friday said insurance proceeds would be substantially used to pay to settle the claims brought on behalf of stockholders who bought Emergent's stock between March 10, 2020, and Nov. 4, 2021.
The lawsuit was originally filed in 2021.
The proposed settlement, which is subject to court approval, includes no admission of liability or wrongdoing by Emergent or any current or former Emergent officers, directors or employees, and will resolve all claims against the company and other defendants.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 13, 2024 07:13 ET (11:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。